Pharma Quality Europe

	Contact
	Téléphone : Mail : Adresse : VIA POGGI 1 52020 Castelfranco di Sopra (arezzo) Italie Web :

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de Pharma Quality Europe
	Agent-based Distributed Decision Support System for brain tumour diagnosis and prognosis HEALTHAGENTS 2006 - 2008 Sujets : Information Processing, Information Systems, Medicine, Health, Telecommunications Type de contrat : Specific Targeted Research Project Participants : MICRO ART SL ESPAÑA MICRO ART SL Other CALLE BALDIRI I REIXAC 4-6 TR D 08028 ESPAÑA KATHOLIEKE UNIVERSITEIT LEUVEN BELGIQUE-BELGIË KATHOLIEKE UNIVERSITEIT LEUVEN Oude Markt BELGIQUE-BELGIË INSTITUTO DE APLICACIONES DE LAS TECNOLOGIAS DE LA INFORMACION Y DE LAS COMUNICACIONES AVANZADAS - ITACA ESPAÑA INSTITUTO DE APLICACIONES DE LAS TECNOLOGIAS DE LA INFORMACION Y DE LAS COMUNICACIONES AVANZADAS - ITACA Other CAMINO DE VERA S/N 46022 ESPAÑA THE UNIVERSITY OF EDINBURGH UNITED KINGDOM THE UNIVERSITY OF EDINBURGH Education OLD COLLEGE, SOUTH BRIDGE UNITED KINGDOM UNIVERSITAT AUTONOMA DE BARCELONA ESPAÑA UNIVERSITAT AUTONOMA DE BARCELONA Education CAMPUS UNIVERSITARI S/N 08193 ESPAÑA UNIVERSITY OF SOUTHAMPTON UNITED KINGDOM UNIVERSITY OF SOUTHAMPTON Education SO17 1BJ Highfield UNITED KINGDOM THE UNIVERSITY OF BIRMINGHAM UNITED KINGDOM THE UNIVERSITY OF BIRMINGHAM Edgbaston UNITED KINGDOM UNIVERSITAT DE VALENCIA ESPAÑA UNIVERSITAT DE VALENCIA Education Avenida Blasco Ibañez 13 ESPAÑA PHARMA QUALITY EUROPE Italy PHARMA QUALITY EUROPE Industry VIA POGGI 1 Italy Hide objective The diagnosis and treatment of brain tumours is typically based on clinical symptoms, radiological appearance and often a histopathological diagnosis of a biopsy. However, treatment response of histologically or radiologically similar tumours can vary widely, particularly in children. Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique for determining the tissue biochemical composition (metabolomic profile) of a tumour. Additionally, the genomic profile, determined using DNA micro-arrays, facilitates the classification of tumour grades and types not trivially distinguished by morphologic appearance. We argue that this new information for classifying tumours along with clinical data should be securely and easy accessible in order to improve the diagnosis and prognosis of tumours. All data will be stored anonymously, and securely through a network of Data Marts based on all this information acquired and stored at centres throughout Europe. This network will grant bona-fide access to an organisation in return for its contribution of clinical data to a distributed Data Warehouse (d-DWH)/Decision Support System (d-DSS). An ad hoc agent-based architecture will negotiate a distributed diagnostic tool for brain tumours, implement data mining techniques, transfer clinical data and extract information. The distributed nature of our approach will help the users to observe local centre policies for sharing information whilst allowing them to benefit from the use of the d-DWH. Moreover, it will permit the design of local centres targeting a specific patient population. We will form a consortium encompassing a wide range of talent from Universities, SME and Hospitals. The d-DWH/d-DSS, the MRS installed base and the expertise of the consortium will provide the foundations for the first EU grid for brain tumour diagnosis and prognosis. We will profit from a world-class clinical data exchange network to address one of the most pernicious diseases of our time: cancer Source : cordis